News >

Surgery Remains Imperative in Biomarker-Driven NSCLC Era

Gina Columbus @ginacolumbusonc
Published: Thursday, Feb 22, 2018

 David Mason, MD

David Mason, MD
Amid the ongoing explosion of immunotherapy and targeted agents in non–small cell lung cancer (NSCLC), surgery remains a key component of the armamentarium.

State of the Science Summit™ on Non–Small Cell Lung Cancer, Mason, chief of thoracic oncology and lung transplantation at Baylor University Medical Center, addressed the evolving role of surgery for patients with NSCLC.

OncLive®: Please provide an overview of your discussion.

Mason: The main topics that I wanted to cover were how biomarkers have impacted the practice of surgery and where the 2 intersect, as well as where the future of surgical resection might be in light of what we are learning today regarding biomarkers. 

Can you expand on how the 2 have comingled and the impact on surgery?

They have intermingled in several areas. One is to obtain tissue [from surgery] and put people on trials to generate more knowledge about the general genomics of lung cancer. Two, we are really looking at where biomarker therapies are intersecting with lung cancer. Those primarily are in the adjuvant setting, or treatment after lung cancer resection.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x